Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Debt to Equity (2020 - 2023)

Historic Debt to Equity for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Q1 2023 value amounting to $0.01.

  • Mirum Pharmaceuticals' Debt to Equity fell 5785.55% to $0.01 in Q1 2023 from the same period last year, while for Mar 2023 it was $0.01, marking a year-over-year decrease of 5785.55%. This contributed to the annual value of $0.01 for FY2022, which is 5378.19% down from last year.
  • According to the latest figures from Q1 2023, Mirum Pharmaceuticals' Debt to Equity is $0.01, which was down 5785.55% from $0.01 recorded in Q4 2022.
  • Mirum Pharmaceuticals' 5-year Debt to Equity high stood at $0.02 for Q2 2021, and its period low was $0.01 during Q1 2021.
  • In the last 4 years, Mirum Pharmaceuticals' Debt to Equity had a median value of $0.01 in 2021 and averaged $0.01.
  • Its Debt to Equity has fluctuated over the past 5 years, first surged by 16378.35% in 2022, then tumbled by 5785.55% in 2023.
  • Over the past 4 years, Mirum Pharmaceuticals' Debt to Equity (Quarter) stood at $0.01 in 2020, then surged by 126.07% to $0.02 in 2021, then plummeted by 53.78% to $0.01 in 2022, then grew by 0.63% to $0.01 in 2023.
  • Its last three reported values are $0.01 in Q1 2023, $0.01 for Q4 2022, and $0.01 during Q3 2022.